Trials / Recruiting
RecruitingNCT06441994
Clinical Trial of Targeted Alpha Therapy Using [At-211]PSMA-5 for Prostate Cancer
A Phase I Investigator-initiated Clinical Trial of a Novel Targeted Alpha Therapy Using [At-211]PSMA-5 for Patients With Castration-resistant Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Osaka University · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
PSW-1025 is administered intravenously to patients with castration-resistant prostate cancer to evaluate its tolerability, safety, pharmacokinetics, absorbed dose, and efficacy, as well as to determine the recommended dose for Phase II.
Detailed description
PSW-1025 is administered intravenously to patients with castration-resistant prostate cancer to evaluate its tolerability, safety, pharmacokinetics, absorbed dose, and efficacy, as well as to determine the recommended dose for Phase II. PSW-1025 (\[At-211\]PSMA-5) is an alpha-ray-emitting drug labeled with Astatine (At-211) that targets PSMA (Prostate Specific Membrane Antigen).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PSW-1025 | PSMA (prostate specific membrane antigen)-targeted alpha therapy drug labeled with Astatine (At-211) |
Timeline
- Start date
- 2024-05-24
- Primary completion
- 2027-03-31
- Completion
- 2027-03-31
- First posted
- 2024-06-04
- Last updated
- 2025-07-31
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT06441994. Inclusion in this directory is not an endorsement.